Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularSTU:LHU -1.40%98 Cyclically Adjusted PS Ratio is 9.33 as of Aug. 13, 2026, which is 15% above its 10-year median of 8.14. GuruFocus rates STU:LHU with a GF Score™ of 98/100 and a GF Value™ of €81.85 (Modestly Undervalued). Among 526 Medical Devices & Instruments companies, LeMaitre Vascular ranks worse than 86.88% on this metric.
The historical rank and industry rank for LeMaitre Vascular's Cyclically Adjusted PS Ratio or its related term are showing as below:
STU:LHU'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.47 Med: 8.14 Max: 14.73
Current: 9.5
During the past years, LeMaitre Vascular's highest Cyclically Adjusted PS Ratio was 14.73. The lowest was 4.47. And the median was 8.14.
STU:LHU's Cyclically Adjusted PS Ratio is ranked worse than 86.88% of 526
companies
in the Medical Devices & Instruments industry
Industry Median: 2.305
vs STU:LHU: 9.50
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
LeMaitre Vascular's adjusted revenue per share data for the three months ended in Jun. 2026 was €2.490. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.56 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
LeMaitre Vascular (STU:LHU) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
LeMaitre Vascular Cyclically Adjusted PS Ratio Related Terms
LeMaitre Vascular Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular Cyclically Adjusted PS Ratio Chart
STU:LHU vs PLSE, XRAY, ATRC: Cyclically Adjusted PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Cyclically Adjusted PS Ratio falls into.
LeMaitre Vascular Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
LeMaitre Vascular's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 9.33 mean?
LeMaitre Vascular (STU:LHU) has a Cyclically Adjusted PS Ratio of 9.33 as of Aug. 13, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on LeMaitre Vascular and its competitors. This is 15% above median its historical median of 8.14. Over the past decade, LeMaitre Vascular's Cyclically Adjusted PS Ratio has ranged from 4.47 to 14.73. According to the industry distribution chart, LeMaitre Vascular ranks #457 out of 526 companies in the Medical Devices & Instruments industry, placing it in the top 86.9%.
Is LeMaitre Vascular's Cyclically Adjusted PS Ratio too high?
LeMaitre Vascular's current Cyclically Adjusted PS Ratio of 9.33 is 15% above median its 10-year median of 8.14. Over the past 10 years, this metric has ranged from a low of 4.47 to a high of 14.73. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.31. LeMaitre Vascular's value of 9.33 is 304.8% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #457 out of 526 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Cyclically Adjusted PS Ratio compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #457 out of 526 companies for Cyclically Adjusted PS Ratio. This places LeMaitre Vascular in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.31. LeMaitre Vascular's value of 9.33 is 304.8% above this benchmark. Historically, LeMaitre Vascular's own Cyclically Adjusted PS Ratio has ranged from 4.47 to 14.73 over the past decade. While the company's 10-year median is 8.14 vs. the industry median of 2.31, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.31, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current Cyclically Adjusted PS Ratio of 9.33 is 304.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current Cyclically Adjusted PS Ratio is 9.33, which is 15% above median its own 10-year median of 8.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (STU:LHU) is currently considered Modestly Undervalued. The stock's GF Value™ is €81.85, compared to a current price of €70.50 — trading 13.9% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 9.33, which is 15% above median its 10-year median of 8.14 and 304.8% above the Medical Devices & Instruments industry median of 2.31. LeMaitre Vascular's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For LeMaitre Vascular (STU:LHU), the current Cyclically Adjusted PS Ratio is 9.33 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (STU:LHU) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of €70.50 is trading 13.9% below its estimated GF Value™ of €81.85.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for STU:LHU:
Cyclically Adjusted PS Ratio: 9.33 (15% above median its 10-year median of 8.14)
GF Value™: €81.85 vs. price of €70.50 (13.9% below fair value)
Industry Position: 304.8% above the Medical Devices & Instruments median (#457 of 526)
No single metric tells the full story. See the STU:LHU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
98GF Score
Get the complete analysis for STU:LHU
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LHU has been successfully added to your 
